[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"non-small-cell-lung-cancer-stage-iiic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:non-small-cell-lung-cancer-stage-iiic":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":20,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100612199",false,"NCT07250477","Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer","Inclusion Criteria:\n\n* Participants must have histologically confirmed non-small cell lung cancer that is metastatic or unresectable (stage IIIC or IV), deemed appropriate to receive standard of care immune checkpoint inhibitor-based therapy given with palliative intent.\n* Age ≥18 years at the time of consent.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥50%).\n* Ability to understand and willingness to sign the informed consent form (ICF).\n* Stated ability and willingness to adhere to all protocol requirements while on study\n\nExclusion Criteria:\n\n* Tumor with known sensitizing alteration in ALK, EGFR, HER2, MET exon 14, NTRK, RET, or ROS1.\n* Medical comorbidities precluding immune checkpoint inhibitor-based therapy per treating investgator's discretion.\n* Previous systemic therapy for metastatic Stage IIIC or IV NSCLC. Patients who previously completed systemic therapy for early stage or locally advanced NSCLC ≥ 80 days prior to trial registration are eligible for inclusion.\n* Any condition that in the opinion of the investigator would interfere with the participant's safety or compliance while on study","ALL","18 Years",{"count":17,"type":18},56,"ESTIMATED","INTERVENTIONAL",[21],"PHASE2","This is a phase 2, pragmatic, 1:1 randomized, open-label study that evaluates risk-adapted, proteomic-guided systemic therapy to improve 12-month progression free survival (PFS) among patients with previously untreated advanced non-small cell lung cancer.",[24,25,26,27,28],"Non-small Cell Lung Cancer Stage IIIC","Non-small Cell Lung Cancer Stage IV","Non Small Cell Lung Cancer","Non-small Cell Lung Cancer Metastatic","Non-small Cell Lung Cancer Unresectable","RECRUITING","2026-02-04",{"date":32,"type":33},"2026-02-09","ACTUAL",{"date":35,"type":33},"2026-01-30",{"date":37,"type":18},"2036-12",{"name":39,"class":40},"University of California, Davis","OTHER",""]